Rubella is still a problem in Europe - The importance of adequate protection for pregnant women;Rubella fortfarande ett problem i Europa - Viktigt att gravida har fullgott skydd

Lakartidningen

Volumn 101, Issue 49, 2004, Pages 3994-3999

  Johansen, Kari ^a   Sjödin, Marie ^b   Westrell Oskarsson, Linn ^b   Arneborn, Malin ^c   Åkerlind, Britt ^d   Forsgren, Marianne ^b  

^a Avdelningen Virologi/avdelningen I   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Universitetssjukhuset I Linkoping ^*  (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RUBELLA VACCINE;

EUROPE; HUMAN; PREGNANT WOMAN; RUBELLA; SHORT SURVEY;

EUROPE; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RUBELLA; RUBELLA VACCINE; SWEDEN;

EID: 10844246341     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Strategic plan for measles and congenital rubella infection in the European region of WHO. http://www.euro.who.int/document/e81567.pdf
2. Forrest JM, Turnbull FM, Sholler GF, Hawker RE, Martin FJ, Doran TT, et al. Gregg's congenital rubella patients 60 years later. Med J Aust 2002;177:664-7.
3. Cooper LZ, Alford CA. Rubella. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and the newborn infant. 5th ed. Philadelphia: WB Saunders; 2001. p. 347-88.
4. Davidkin I, Peltola H, Leinikki P, Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000;18:3106-12.
5. Morgan-Capner P, Miller E, Vurdien JE, Ramsay ME. Outcome of pregnancy after maternal reinfection with rubella. Communicable Disease Report (Lond Engl Rev)1991;1:R57-9. http://www.hpa.org.uk/cdr/CDRreview/1991/cdrro691.pdf
6. Böttiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women post-partum) and 13 years of a general two-dose vaccination. Vaccine 1997;15:1538-44.
7. Forsgren M, Jorup-Rönström C, Svedmyr A, von Sydow M. Är gammaglobulin vid rubellaexposition under tidig graviditet meningsfylld profylax? Läkartidningen 1976;73:308-11.
8. Barr B, Böttiger M, Eriksson M, Forsgren M, Lundström R. Det rubellaskadade barnet - kommer del att försvinna? Läkartidningen 1979;76:3511-21.
9. Vaccinationsstatistik från barnavårdscentralerna och skolorna. http://www.smittskyddsinstitutet.se
10. Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002;110:957-63.
11. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001;19:3632-5.
12. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002;324:393-6.
13. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002;347:1477-82.
14. Data rapporterade till WHO för år 2003, erhållna och publiceras med tillstånd från N Emiroglu, WHO Regional Office for Europe.
15. Rubella vaccines. WHO position paper. Weekly epidemiological record 2000; 75, 161-72. http://www.who.int/wer/archives/en/
16. Vynnycky E, Gay NJ, Cutts FT. The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome. Vaccine 2003;21:2708-19.
17. Olin P, Carlsson RM, Hallander H, Ljungman M, Svensson Å, et al. Vaccinationsuppföljning. Seroepidemisk tvärsnittsstudie 1997, slutrapport. Smittskyddsinstitutets rapportserie nr 3:2004. Se vaccinationer - aktuella rapporter. http://www.smittskyddsinstitutet.se
18. Tookey P, Molyneaux P, Helms P. UK case of congenital rubella can be linked to Greek cases. BMJ 2000;321:766.